Clinical Trial Update: Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating whether olmesartan medoxomil benefits the cardiovascular system by arterial protection in metabolic syndrome and hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Metabolic Syndrome

Drugs mentioned

• OLMESARTAN MEDOXOMIL (olmesartan medoxomil)

Snippet

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | Conditions: Metabolic Syndrome, Hypertension | Phase 3 | Status: COMPLETED